



12 April 2023

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call Notification

ImpediMed Limited (**ImpediMed** or the **Company**) (ASX:IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 31 March 2023, on Monday 17th April 2023.

Investors are invited to join a live conference call and Q&A hosted by Managing Director and CEO, Rick Valencia at 9.30am (AEST) on Monday 17th April 2023.

To pre-register, please follow this link:

<https://s1.c-conf.com/diamondpass/10029861-svnw7h.html>

Registered participants will receive a calendar notification with dial in details and a PIN for fast-track access to the call.

Approved for release by the Managing Director and CEO, Mr Rick Valencia.

Contact Details

Investor relations Contact:

Hannah Howlett

WE Communications

T: +61 (0) 4 5064 8064

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.